Diamond Equity Brokers Increase Earnings Estimates for BHST

Key Points

• Analysts at Diamond Equity have increased their Q3 2026 EPS estimate for BioHarvest Sciences from $0.03 to $0.06 per share, with a full-year estimate of ($0.80) per share.
• BioHarvest Sciences' shares experienced a 0.5% decline on Thursday, trading at $9.44, with a market capitalization of $155.05 million.
• Several institutional investors, including TD Waterhouse Canada Inc. and Magnus Financial Group LLC, have recently increased their stakes in BioHarvest Sciences.

BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Stock analysts at Diamond Equity lifted their Q3 2026 earnings per share (EPS) estimates for shares of BioHarvest Sciences in a report issued on Wednesday, August 13th. Diamond Equity analyst H. Diamond now forecasts that the company will earn $0.06 per share for the quarter, up from their prior forecast of $0.03. The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.80) per share. Diamond Equity also issued estimates for BioHarvest Sciences' Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.08 EPS.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.04). BioHarvest Sciences had a negative net margin of 39.95% and a negative return on equity of 11,357.84%. The business had revenue of $8.52 million for the quarter, compared to the consensus estimate of $8.53 million.

Separately, Craig Hallum started coverage on BioHarvest Sciences in a report on Monday, May 5th. They issued a "buy" rating and a $15.00 price target on the stock.

BioHarvest Sciences Stock Up 1.1%

NASDAQ:BHST traded up $0.10 on Thursday, hitting $9.32. The stock had a trading volume of 74,866 shares, compared to its average volume of 19,022. The business's fifty day moving average is $7.41 and its 200 day moving average is $6.48. The company has a market cap of $153.03 million, a PE ratio of -13.31 and a beta of 0.68. BioHarvest Sciences has a 52 week low of $4.66 and a 52 week high of $9.90.

Institutional Trading of BioHarvest Sciences

Several institutional investors and hedge funds have recently modified their holdings of BHST. Magnus Financial Group LLC increased its position in shares of BioHarvest Sciences by 105.0% during the first quarter. Magnus Financial Group LLC now owns 71,733 shares of the company's stock valued at $444,000 after acquiring an additional 36,733 shares during the last quarter. True North Advisors LLC increased its position in BioHarvest Sciences by 7.6% in the first quarter. True North Advisors LLC now owns 44,391 shares of the company's stock worth $275,000 after buying an additional 3,120 shares during the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new stake in BioHarvest Sciences in the fourth quarter worth $69,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.